小柯机器人

羟氯喹无法用于抵御SARS-CoV-2感染
2020-07-25 12:40

德国哥廷根大学Stefan Pöhlmann、Markus Hoffmann等研究人员合作发现,羟氯喹(HCQ)无法用于抵御SARS-CoV-2感染。该研究于2020年7月22日在线发表于《自然》。

研究人员评估了HCQ的体外以及在SARS-CoV-2感染的猕猴中的抗病毒活性。HCQ在非洲绿猴肾细胞(VeroE6)中显示抗病毒活性,但在重组的人气道上皮模型中却没有。在猕猴中,与安慰剂相比,在峰值病毒负荷前后,单独或与阿奇霉素(AZTH)组合使用时,研究人员测试了不同的治疗策略。
 
HCQ和HCQ+AZTH均未显示对任何测试区域的病毒载量水平有显著影响。当该药物用作暴露前预防(PrEP)时,HCQ不能预防感染。这些发现表明,HCQ单独或与AZTH一起使用均无法用于人类COVID-19治疗。
 
COVID-19已迅速成为一种大流行病,目前尚无抗病毒药物或疫苗可用。目前正在进行一些临床研究,以评估已在体外证明抗病毒功效的药物。在这些候选药物中,HCQ已被全世界数千人接受,但仍缺乏有关HCQ治疗COVID-19的确切证据。
 
附:英文原文

Title: Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Author: Pauline Maisonnasse, Jrmie Guedj, Vanessa Contreras, Sylvie Behillil, Caroline Solas, Romain Marlin, Thibaut Naninck, Andres Pizzorno, Julien Lemaitre, Antonio Gonalves, Nidhal Kahlaoui, Olivier Terrier, Raphael Ho Tsong Fang, Vincent Enouf, Nathalie Dereuddre-Bosquet, Angela Brisebarre, Franck Touret, Catherine Chapon, Bruno Hoen, Bruno Lina, Manuel Rosa Calatrava, Sylvie van der Werf, Xavier de Lamballerie, Roger Le Grand

Issue&Volume: 2020-07-22

Abstract: COVID-19 has rapidly become a pandemic for which no antiviral drug or vaccine is yet available2–4. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals worldwide but definitive evidence for HCQ efficacy in treatment of COVID-19 is still missing6,7,17,18. We evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (VeroE6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to placebo, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor HCQ+AZTH showed a significant effect on the viral load levels in any of the tested compartments. When the drug was used as a pre-exposure prophylaxis (PrEP), HCQ did not confer protection against acquisition of infection. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral treatment for COVID-19 in humans.

DOI: 10.1038/s41586-020-2558-4

Source: https://www.nature.com/articles/s41586-020-2558-4

Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:69.504
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html


本期文章:《自然》:Online/在线发表

分享到:

0